HIV Populations
Early Time-limited Treatment Leads to Better Outcomes for Infants with HIV
- Details
- Category: Children & Adolescents
- Published on Wednesday, 28 August 2013 00:00
- Written by Liz Highleyman
Infants with HIV who start antiretroviral therapy (ART) immediately after birth had a lower risk of disease progression or death and were able to safely interrupt treatment longer than children who started ART later, according to findings from the long-running CHER study published in the August 22, 2013, advance online edition of The Lancet.
IAS 2013: Lower-dose Lopinavir/Ritonavir Reduces Side Effects, Maintains Viral Control in HIV+ Children
- Details
- Category: Children & Adolescents
- Published on Wednesday, 14 August 2013 00:00
- Written by Carole Leach-Lemens
Low dose lopinavir/ritonavir (Kaletra or Aluvia) -- 70% of the standard dose -- worked as well as the standard dose in maintaining viral suppression, but with less dyslipidemia, among children with HIV in Thailand, Thanyawee Puthanakit reported on behalf of the HIVNAT 152 PEARL study at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) in Kuala Lumpur.
HIV+ Women May Experience More Severe Menopause Symptoms
- Details
- Category: Women & HIV
- Published on Thursday, 01 August 2013 00:00
- Written by Liz Highleyman
Women with HIV on average experience more severe hot flashes around the time of menopause than HIV negative women, and they interfere more with daily life, according to a study described in the July 1, 2013, advance online edition of the journal Menopause.
IAS 2013: Women Who Start Option B+ ART During Pregnancy Often Lost to Follow-up
- Details
- Category: Pregnancy & HIV MTCT
- Published on Wednesday, 07 August 2013 00:00
- Written by Leslie Odendal
Women who begin HIV treatment during pregnancy or while breastfeeding, prior to the CD4 cell threshold previously recommended for starting treatment (350 cells/mm3), were significantly more likely to be lost to follow-up than women who started treatment at the general treatment threshold, Malawian researchers reported at the recent 7th International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention in Kuala Lumpur.
IAS 2013: Experts Discuss Role of Drug Policy in HIV, Hepatitis, and TB Epidemics
- Details
- Category: People Who Inject Drugs
- Published on Tuesday, 02 July 2013 00:00
- Written by Liz Highleyman
International drug policy must shift from prohibition to public health in order to reduce harms to individuals and societies, including fueling the spread of HIV, hepatitis, and tuberculosis, experts from a range of disciplines agreed at 2 sessions held during the 7th IAS Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2013) this week in Kuala Lumpur.
Web Design and Development by